Six Years, One Prescription Pad, and the Medical Structure Nobody Built

The clinic denied it on day one. The prescription pad on which Ruti Aga's knee treatment was written, the clinic's records say, was never theirs. The pad allegedly came from a former employee's old stock. And the person who wrote on it was a family member with no medical registration. The entire case rests on those three sentences; the rest is arithmetic.

The drug is methylprednisolone, a glucocorticoid anti-inflammatory that the WADA Code prohibits only in-competition, by injection or oral route. It was found in Aga's sample after she won a half marathon in China in March. She is 32, the 2026 Tokyo Marathon champion, and a three-time World Marathon Major runner-up. The sanction runs six years, counted from 10 September.

I start with documents because in sports-governance cases the size of the punishment is often set by the paperwork rather than the offence. Four of the six years here come from the tampering charge — the creation and presentation of a false document. The remainder comes from the presence of a prohibited substance in competition. If the injection genuinely happened for the knee, then the sanction's real foundation is the medical file, not the medicine.

Road racing's economy is the part most readers skip. At the top of the marathon and half marathon ladder, income is dominated by appearance fees and podium bonuses rather than global sponsorship. Below that sits a layer of label races where organisers bring in athletes, pay them, and where the testing footprint is determined by the local anti-doping body and targeted Athletics Integrity Unit work rather than by the race's commercial profile. High fee, low surveillance: a well-known exposure zone for the mid-tier elite.

The March race in China appears to belong to that layer. No name, no winning time, no course profile, no sample type, no year of decision. Those gaps are not trivia. Without them, neither the athlete's current form nor the quality of that win can be placed in any reliable column. Where electronic timing and course certification are themselves absent, reconstructing a doping timeline means building on inference.

What can be computed is the calendar. Glucocorticoids are prohibited only in-competition. A genuine, documented, out-of-competition injection with proper clearance is a fully legal route. A detectable presence on race day is not. The question is therefore not whether an injection happened; it is when it happened, and who manufactured the paper around it.

That is where the infrastructure question actually sits. Knee pain is an ordinary occupational hazard for an elite marathoner; running more than two thousand kilometres a year loads the patellofemoral joint in ways that make it close to inevitable. An athlete whose team includes a licensed physician who understands therapeutic use exemptions schedules the injection outside competition, records it, and ends the season with a file. An athlete treated through a family member writing on an old pad ends the season with a six-year ban for the same injection. When a sprinter loses time because there is no track, that is one failure of infrastructure; when a marathoner loses a career because there is no licensed medical channel, it is the same failure wearing different clothes.

In this case a person was punished, but a system failed. Had the decision shown that Aga's setup included a registered physician and that she bypassed him for a family channel, the responsibility would rest entirely with the athlete. The published record contains no such medical structure. Ethiopia's high-altitude pipeline routinely pairs a personal coach with an agent-managed race calendar, and just as routinely leaves out a medically literate support team. That absence is an institutional gap, and the federation and management agency own it, not the runner.

The number that matters now is not a time but an annulment. The March half marathon title, prize money and ranking points will all be disqualified, because that is the competition at which the sample was collected. The 2026 Tokyo title is untouched by this decision. One line survives in the record book and one is deleted, and I keep those two columns separate, because an erased number and an erased memory are not the same kind of deletion.

This is how I reconstruct these cases from a desk. In 2026 I borrowed the World Cup's broadcast tagging method and started logging reaction times on archived race clips; in 2026, when the national championships were cancelled, I built an archive out of 41 phone interviews. Both taught the same rule: missing data does not get filled with inference, it gets written down as a gap. The gap here is the silence around the medical setup.

The headlines say a six-year ban for a fake prescription, which frames a fraud story. But an athlete with one Major win and three Major runner-up finishes earns primarily through appearance fees and podium bonuses, not global endorsements. Six years away removes nearly all of that income, and coming back from 32 means coming back at 38. No woman has returned at that age to win a marathon major, at least not in a way a federation could build a plan on. The sanction is effectively a career ban even though it is written as a fixed term.

I would attach a condition rather than a verdict. If the full decision shows Aga chose the family channel over an available registered physician, the system-failure argument in this piece weakens and the case reduces to straightforward fraud. The published summary does not carry that evidence; if it emerges, the arithmetic changes.

The question ahead is administrative. Publishing a minimum testing footprint for appearance-fee races would shrink this risk zone; making a registered physician mandatory inside an athlete's entourage would stop an old prescription pad from ending a career. What that circuit's races disclose next March is the thing worth watching.